ATC Group: C08C Selective calcium channel blockers with mainly vascular effects

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C08C in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C08 Calcium channel blockers
3 C08C Selective calcium channel blockers with mainly vascular effects

Group C08C contents

Code Title
C08CA Dihydropyridine derivatives
C08CX Other selective calcium channel blockers with mainly vascular effects

Active ingredients in C08C

Active Ingredient Description
Amlodipine

Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.

Azelnidipine
Barnidipine

Barnidipine is a lipophilic 1,4-dihydropyridine calcium antagonist showing high affinity for the calcium channels of the smooth muscle cells in the vascular wall.

Benidipine
Cilnidipine
Clevidipine

Clevidipine is a dihydropyridine L-type calcium channel blocker. L-type calcium channels mediate the influx of calcium during depolarization in arterialsmooth muscle. Experiments in anesthetized rats and dogs show that clevidipine reduces mean arterial blood pressure by decreasing systemic vascular resistance.

Felodipine

Felodipine is a vascular selective calcium antagonist, which lowers arterial blood pressure by decreasing systemic vascular resistance. Felodipine is effective in all grades of hypertension.

Isradipine

Isradipine is a potent dihydropyridine calcium channel blocker with selective activity on voltage-gated calcium channels (L-type or “long acting”). Isradipine has a higher affinity for such calcium channels in arterial smooth muscle than for those in the myocardium. It thus dilates arterial vascular beds, in particular those of the heart, brain and skeletal muscle without depressing cardiac function.

Lacidipine

Lacidipine is a specific and potent calcium antagonist with a predominant selectivity for calcium channels in the vascular smooth muscle. Its main action is to dilate peripheral arterioles, reducing peripheral vascular resistance and lowering blood pressure.

Lercanidipine

Lercanidipine is a calcium antagonist of the dihydropyridine group and inhibits the transmembrane influx of calcium into cardiac and smooth muscle. The mechanism of its antihypertensive action is due to a direct relaxant effect on vascular smooth muscle thus lowering total peripheral resistance.

Levamlodipine

Levamlodipine is the pharmacologically active isomer of amlodipine, a long-acting calcium channel blocker. It is used for the treatment of hypertension in adults and pediatric patients, to lower blood pressure.

Manidipine

Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.

Nicardipine

Nicardipine is a second generation slow calcium channel inhibitor, and belongs to the phenyl-dihydropyridine group. Nicardipine has a greater selectivity for L-type calcium channels in vascular smooth muscle than cardiac myocytes. Nicardipine produces smooth muscle relaxation and marked peripheral vasodilatation.

Nifedipine

Nifedipine is a calcium antagonist of the 1,4-dihydropyridine type. Calcium antagonists reduce the transmembranal influx of calcium ions through the slow calcium channel into the cell. As a specific and potent calcium antagonist, nifedipine acts particularly on the cells of the myocardium and the smooth muscle cells of the coronary arteries and the peripheral resistance vessels. The main action of nifedipine is to relax arterial smooth muscle, both in the coronary and peripheral circulation. Nifedipine Tablets are formulated to achieve controlled delivery of nifedipine in a release profile sufficient to enable once-daily administration to be effective in clinical use.

Nilvadipine

Nilvadipine at very low concentrations inhibits the influx of calcium into the cell of the smooth vascular musculature and thereby cause vasodilatation. The myogenic vascular-wall tonus is reduced and the peripheral vascular resistance diminished. This in turn results in an antihypertensive effect.

Nimodipine

Nimodipine is a dihydropyridine calcium channel blocker with particular cerebrovascular effect. Nimodipine increases cerebral perfusion, particularly in poorly perfused areas, by arterial dilatation, an effect which is proportionately greater in smaller than in larger vessels.

Nisoldipine

Nisoldipine is a member of the dihydropyridine class of calcium channel antagonists (calcium ion antagonists or slow channel blockers) that inhibit the transmembrane influx of calcium into vascular smooth muscle and cardiac muscle. Because the contractile process of vascular smooth muscle is dependent upon the movement of extracellular calcium into the muscle through specific ion channels, inhibition of the calcium channel results in dilation of the arterioles.

Nitrendipine

Nitrendipine is a dihydropyridine calcium channel blocker. It is used in the treatment of primary hypertension to decrease blood pressure.

Related product monographs

Title Information Source Document Type  
ADALAT Tablet Medicines and Medical Devices Safety Authority (NZ) MPI, EU: SmPC
AMLOBE Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
AMLORINE Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
CARDENE Hard capsule Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
CARDENE IV Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
CLEVIPREX Emulsion for infusion FDA, National Drug Code (US) MPI, US: SPL/PLR
CONJUPRI Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
FENAMON SR Modified release tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
ISTIN Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
NIDEF Prolonged release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
NIFELAT Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
NIMOTOP 0.02% Solution for infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
NIMOTOP Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
NORVASC Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
PLENDIL Prolonged-release tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
PROCARDIA Capsule FDA, National Drug Code (US) MPI, US: SPL/Old
PROCARDIA XL Extended release tablet FDA, National Drug Code (US) MPI, US: SPL/Old
VASEXTEN Modified release capsules European Medicines Agency (EU) MPI, EU: SmPC
ZANIDIP Film-coated tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC